Johnson & Johnson invests $2 billion in a new biopharmaceutical manufacturing facility in Holly Springs, NC creating 120 jobs. Part of a $55B US expansion for advanced medicine production.
Johnson & Johnson $2 billion manufacturing facility Holly Springs North Carolina biopharma jobs
Holly Springs, North Carolina, US – In a significant move to onshore its production capabilities healthcare giant Johnson & Johnson (J&J) has announced a major $2 billion investment to establish a new state-of-the-art manufacturing facility in Holly Springs, North Carolina.
The new 160,000-square-foot plant will be constructed on Fujifilm’s biopharmaceutical campus a hub for life sciences innovation. This strategic expansion is a core part of J&J’s broader commitment to manufacture the majority of its advanced medicines within the United States enhancing supply chain resilience and domestic production capacity.
Strategic Expansion in a Biopharma Hub
The Holly Springs facility represents a strategic co-location with existing industry infrastructure. By building on Fujifilm’s dedicated campus, J&J can leverage synergies and a established ecosystem for biopharmaceutical manufacturing. The project is expected to create approximately 120 new high-skill jobs over the next decade, contributing to the region’s growing status as a “BioPharma Crescent.”
This investment is a direct component of the ambitious $55 billion, four-year US manufacturing and R&D investment plan announced by the company in March. It underscores a deliberate strategy to concentrate advanced manufacturing close to its primary research and development centers.
Part of a Broader $55 Billion US Investment Wave
The Holly Springs site is not an isolated project but part of a massive nationwide infrastructure push by J&J:
- Wilson, NC Facility: Construction is already underway at another North Carolina site in Wilson. That project is anticipated to employ over 500 people once operational and generate roughly 5,000 construction jobs.
- Future Announcements: The company has signaled it will outline additional advanced manufacturing projects and expansions at existing sites in the coming months.
This series of investments aims to solidify the infrastructure needed for the development and production of cutting-edge treatments across critical therapeutic areas, including:
- Oncology
- Neuroscience
- Immunology
- Cardiovascular Disease
- Robotic Surgery
Leadership’s Commitment to US Manufacturing
Joaquin Duato, Chair and Chief Executive Officer of Johnson & Johnson, emphasized the company’s deep-rooted commitment to American manufacturing: “Johnson & Johnson has more manufacturing facilities in the US than in any other country, and we continue to strengthen our presence here.”
This commitment goes beyond corporate strategy; it is a response to growing national priorities around healthcare security, job creation, and maintaining a competitive edge in advanced pharmaceutical manufacturing on the global stage.
The $2 billion Holly Springs facility is a powerful testament to this vision, ensuring that the next generation of medical breakthroughs is not only discovered but also manufactured on US soil.